Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases
Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets. Longaevus Technologies is a company builder with dedicated to longevity, with an all-round approach to reversing aging based on its multiple hallmarks. Longaevus Technologies combines the expertise of an international team of renowned scientists from major universities and organizations, academics and industry experts to reach the common goal of reversing aging.
After being in stealth mode for a year, Elastin Biosciences, an innovative biotech company spun off from Longaeuvus Technologies, has unveiled a groundbreaking discovery in the realm of elastin-related health. Elastin Biosciences, with its core team comprising Chief Scientist Alexey Moskalev, and Director of Research Alexander Fedintsev, CEO Sherif Idriss, has successfully performed experiments in Oxford and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in-vivo. Longaevus Technologies currently has 3 more companies in stealth mode.
This cutting-edge research promises to offer solutions for individuals affected by elastin-deficiency related diseases and also has the potential to significantly promote healthy longevity. Transitioning from preclinical proof of concept to the pre-IND phase, this development showcases the company's dedication and commitment to pioneering the future of regenerative medicine. In a testament to the importance and potential of this research, Elastin Biosciences has secured an initial funding of $2.5 million. Bolstered by this support, the company is also prepping to launch a Series A funding round to further its mission and research endeavors.
The degradation of elastin, linked with a variety of health issues as well as the natural aging process, has long been on the radar of medical experts. This breakthrough by Elastin Biosciences not only brings renewed hope for those directly afflicted by elastin-deficiency but also charts a path for innovative treatments designed to bolster overall health and longevity.
Elastin Biosciences is now poised to make significant strides in regenerative medicine, ushering in a new era of treatment solutions and healthy aging.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831595786/en/
Contact information
Sherif Idriss
+4917632276520 / sherif@longaevus.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bsure Insights Now Available in the Microsoft Azure Marketplace5.12.2023 15:13:00 EET | Press release
Bsure today announced the availability of Bsure Insights in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. Bsure customers can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management. “Through our application, we give companies insights into their Microsoft users and licenses, giving them the tool they need to optimize their spend and reduce risk on their users, both member and guests,” said Henrik Skalmerud, CEO, Bsure. “We want to share our competency through the app, empowering companies to make informed decisions based on the information we give them, and this is available on the Azure Marketplace platform.” “Microsoft welcomes Bsure Insights to Azure Marketplace, where global customers can find, try, and buy from among thousands of partner solutions,” said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. “Azure Marketplace and trusted partne
Battery Manufacturer Hithium Joins Chile’s Clean Energy Association5.12.2023 15:00:00 EET | Press release
Stationary energy storage specialist Hithium has become a member of Chile’s renewable energy association ACERA. The manufacturer signed with the group at an event it hosted for partners and industry colleagues in Santiago, where Hithium representatives also introduced the company to the regional market and presented its latest product innovations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205316012/en/ Hithium joins ACERA in Chile (Photo: Business Wire) “We are committed to supporting the renewables industry in Chile, which is why it is important for us to join our clean energy sector colleagues here and become a member of ACERA,” said Mizhi Zhang, Hithium Head of Global Business, at the event. “As renewable energy generation grows, energy storage plays a key role in enabling the grid to incorporate clean power in a stable way. A big thanks to all our sector colleagues and partners who joined us tonight to celebrate
Moody’s Launches Moody’s Research Assistant, a GenAI Tool to Power Analytic Insights5.12.2023 15:00:00 EET | Press release
Moody's Corporation (NYSE:MCO) today announced the launch of Moody’s Research Assistant, a first-of-its-kind search and analytical tool powered by generative artificial intelligence (GenAI). Leveraging Moody’s extensive proprietary content and the latest large language models (LLMs), the product helps customers generate new insights from the breadth and depth of Moody’s credit research, data, and analytics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205410924/en/ As the first GenAI-powered research tool commercially available for financial market participants, Moody’s Research Assistant synthesizes vast amounts of information so users can assess lending or investment opportunities, monitor developments, compare entities, and enhance analytical workflows rapidly and at scale. Grounded in Moody’s extensive proprietary content in combination with the latest GenAI technology, Moody’s Research Assistant allows users to gen
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza5.12.2023 15:00:00 EET | Press release
Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza. The grant comes in the context of the wider Pandemic Antiviral Discovery (PAD) initiative. Out of the COVID-19 pandemic experience, jointly with the Novo Nordisk Foundation and the Bill & Melinda Gates Foundation, Open Philanthropy launched the PAD initiative to help catalyse the discovery and early development of novel antiviral medicines in preparation for future pandemics. “We are thrilled that these expert institutions are supporting Exscientia’s capabilities to develop innovative solutions to address significant unsolved health issues, expressed through this grant,” said Professor Ian Goodfellow, Vice President of Antivirals at Exscientia. “If we mana
Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion5.12.2023 15:00:00 EET | Press release
Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura ®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205198764/en/ This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom